Minimal residual disease in acute myeloid leukaemia

被引:162
作者
Hourigan, Christopher S. [1 ]
Karp, Judith E. [2 ]
机构
[1] NHLBI, Myeloid Malignancies Sect, Hematol Branch, Bethesda, MD 20892 USA
[2] Sidney Kimmel Comprehens Ctr Johns Hopkins, Baltimore, MD 21231 USA
基金
美国国家卫生研究院;
关键词
STEM-CELL TRANSPLANTATION; MULTIPARAMETER FLOW-CYTOMETRY; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; INTERNAL TANDEM DUPLICATION; TUMOR GENE-1 EXPRESSION; TIME QUANTITATIVE PCR; COMPLETE REMISSION; PERIPHERAL-BLOOD;
D O I
10.1038/nrclinonc.2013.100
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Technological advances in the laboratory have led to substantial improvements in clinical decision making through the introduction of pretreatment prognostic risk stratification factors in acute myeloid leukaemia (AML). Unfortunately, similar progress has not been made in treatment response criteria, with the definition of 'complete remission' in AML largely unchanged for over half a century. Several clinical trials have demonstrated that high-sensitivity measurements of residual disease burden during or after treatment can be performed, that results are predictive for clinical outcome and can be used to improve outcomes by guiding additional therapeutic intervention to patients in clinical complete remission, but at increased relapse risk. We review these recent trials, the characteristics and challenges of the modalities currently used to detect minimal residual disease (MRD), and outline opportunities to both refine detection and improve clinical use of MRD measurements. MRD measurement is already the standard of care in other myeloid malignancies, such as chronic myelogenous leukaemia and acute promyelocytic leukaemia (APL). It is our belief that response criteria for non-APL AML should be updated to include assessment for molecular complete remission and recommendations for post-consolidation surveillance should include regular monitoring for molecular relapse as standard of care.
引用
收藏
页码:460 / 471
页数:12
相关论文
共 138 条
[1]   Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia [J].
Abdelhamid, Emna ;
Preudhomme, Claude ;
Helevaut, Nathalie ;
Nibourel, Olivier ;
Gardin, Claude ;
Rousselot, Philippe ;
Castaigne, Sylvie ;
Gruson, Berengere ;
Berthon, Celine ;
Soua, Zohra ;
Renneville, Aline .
LEUKEMIA RESEARCH, 2012, 36 (03) :316-323
[2]   Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry [J].
Al-Mawali, Adhra ;
Gillis, David ;
Hissaria, Pravin ;
Lewis, Ian .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (06) :934-945
[3]   The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia [J].
Al-Mawali, Adhra ;
Gillis, David ;
Lewis, Ian .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (01) :16-26
[4]   Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia [J].
Anguille, S. ;
Van Tendeloo, V. F. ;
Berneman, Z. N. .
LEUKEMIA, 2012, 26 (10) :2186-2196
[5]   High frequency of immunophenotype changes in acute myeloid leukemia at relapse:: implications for residual disease detection (Cancer and Leukemia Group B Study 8361) [J].
Baer, MR ;
Stewart, GC ;
Dodge, RK ;
Leget, G ;
Sulé, N ;
Mrózek, K ;
Schiffer, CA ;
Powel, BL ;
Kolitz, JE ;
Moore, JO ;
Stone, RM ;
Davey, FR ;
Carrol, AJ ;
Larson, RA ;
Bloomfield, CD .
BLOOD, 2001, 97 (11) :3574-3580
[6]   Relapse after allogeneic stem cell transplantation [J].
Barrett, A. John ;
Battiwalla, Minoo .
EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (04) :429-441
[7]   Can we include vaccines with stem-cell transplantation? [J].
Barrett, John ;
Rezvani, Katayoun .
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (09) :503-505
[8]   Detection of Minor Clones With Internal Tandem Duplication Mutations of FLT3 Gene in Acute Myeloid Leukemia Using Delta-PCR [J].
Beierl, Katie ;
Tseng, Li-Hui ;
Beierl, Russell ;
Haley, Lisa ;
Gocke, Christopher D. ;
Eshleman, James R. ;
Lin, Ming-Tseh .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2013, 22 (01) :1-9
[9]   How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet [J].
Bene, Marie C. ;
Kaeda, Jaspal S. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (08) :1135-1150
[10]   Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells [J].
Biernacki, Melinda A. ;
Marina, Ovidiu ;
Zhang, Wandi ;
Liu, Fenglong ;
Bruns, Ingmar ;
Cai, Ann ;
Neuberg, Donna ;
Canning, Christine M. ;
Alyea, Edwin P. ;
Soiffer, Robert J. ;
Brusic, Vladimir ;
Ritz, Jerome ;
Wu, Catherine J. .
CANCER RESEARCH, 2010, 70 (03) :906-915